Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhuba, Liia, Tigai, Zhanna, Shek, Dmitrii
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344717/
https://www.ncbi.nlm.nih.gov/pubmed/37457121
http://dx.doi.org/10.20517/cdr.2022.142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344717/
https://www.ncbi.nlm.nih.gov/pubmed/37457121
http://dx.doi.org/10.20517/cdr.2022.142

Ejemplares similares